Log in Register
Menu

TR146 Cell Line

Info

Catalogue Number 151425
Host Human
Tissue Buccal mucosa
Disease Keywords Human neck metastasis
Model Tumour line
Relevance The TR146 cell line represents a potentially unique in vitro model of buccal mucosa. The cell line has been well characterised and is an ideal tool for permeability and absorption studies. Due to morphological similarities and comparable permeability, excised porcine buccal mucosa has been considered a reasonably good model of human buccal mucosa for drug delivery studies. However, for rapid and efficient screening of drug permeability, a cell line generally holds advantages over in vitro models of excised tissue. TR146 therefore represents a good and potentially unique model of human mucosa. The cells form an undifferentiated, non-keratinised stratified epithelium which shares many characteristics of normal buccal mucosa. TR146 has been characterised for permeability of a number of substances of varying molecular weight and hydrophilicity over a range of pH and osmolality. Activity of aminopeptidase, carboxypeptidase and esterase has also been studied and shown to be comparable with that of human buccal epithelium. The cell line is therefore not only a useful model for absorption but also for metabolism studies with enzymatically labile drugs.
Production Details The TR146 cell line originates from a human neck metastasis of a buccal carcinoma, derived from neck node (primary tumour sited in buccal mucosa). Well-differentiated. Female patient, 67 years. Previous radiotherapy (6,000 rads) and neck dissection
Research Area Drug Discovery & Development, Metabolism
Growth/Phenotype Keywords Undifferentiated, non-keratinsed stratified epithelium, normal human mucosa
Recommended Growing Conditions 5% CO2; 37°C, HAMS F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS), Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 3 x 104 cells/cm2
Cellosaurus ID CVCL_2736

References: 16 entries

Pistone et al. 2016. Eur J Pharm Sci. 96:381-389. PMID: 27721043.

Nilsen et al. 2016. Eur J Oral Sci. :. PMID: 27711994.

Iyire et al. 2016. Sci Rep. 6:32498. PMID: 27581177.

Goyer et al. 2016. PLoS One. 11(3):e0149159. PMID: 26933885.

Zeng et al. 2015. Int J Pharm. 495(2):1028-37. PMID: 26403384.

De Ryck et al. 2015. AMB Express. 5:27. PMID: 25995981.

O'Callaghan et al. 2015. Mol Med Rep. :. PMID: 26005189.

Chai et al. 2012. J R Soc Interface. 9(77):3528-38. PMID: 22915635.

Mørck Nielsen et al. 2000. Int J Pharm. 200(2):261-70. PMID: 10867256.

Nielsen et al. 2000. Int J Pharm. 194(2):155-67. PMID: 10692640.

Jacobsen et al. 1999. Eur J Pharm Biopharm. 48(3):217-24. PMID: 10612032.

Nielsen et al. 1999. Int J Pharm. 185(2):215-25. PMID: 10460917.

Nielsen et al. 1999. J Control Release. 60(2-3):223-33. PMID: 10425328.

Pedersen et al. 1999. Drug Dev Ind Pharm. 25(4):463-70. PMID: 10194601.

Jacobsen et al. 1999. Eur J Oral Sci. 107(2):138-46. PMID: 10232463.

Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234.


Add a reference

References: 16 entries

Pistone et al. 2016. Eur J Pharm Sci. 96:381-389. PMID: 27721043.

Nilsen et al. 2016. Eur J Oral Sci. :. PMID: 27711994.

Iyire et al. 2016. Sci Rep. 6:32498. PMID: 27581177.

Goyer et al. 2016. PLoS One. 11(3):e0149159. PMID: 26933885.

Zeng et al. 2015. Int J Pharm. 495(2):1028-37. PMID: 26403384.

De Ryck et al. 2015. AMB Express. 5:27. PMID: 25995981.

O'Callaghan et al. 2015. Mol Med Rep. :. PMID: 26005189.

Chai et al. 2012. J R Soc Interface. 9(77):3528-38. PMID: 22915635.

Mørck Nielsen et al. 2000. Int J Pharm. 200(2):261-70. PMID: 10867256.

Nielsen et al. 2000. Int J Pharm. 194(2):155-67. PMID: 10692640.

Jacobsen et al. 1999. Eur J Pharm Biopharm. 48(3):217-24. PMID: 10612032.

Nielsen et al. 1999. Int J Pharm. 185(2):215-25. PMID: 10460917.

Nielsen et al. 1999. J Control Release. 60(2-3):223-33. PMID: 10425328.

Pedersen et al. 1999. Drug Dev Ind Pharm. 25(4):463-70. PMID: 10194601.

Jacobsen et al. 1999. Eur J Oral Sci. 107(2):138-46. PMID: 10232463.

Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234.


Add a reference

References: 16 entries

Pistone et al. 2016. Eur J Pharm Sci. 96:381-389. PMID: 27721043.

Nilsen et al. 2016. Eur J Oral Sci. :. PMID: 27711994.

Iyire et al. 2016. Sci Rep. 6:32498. PMID: 27581177.

Goyer et al. 2016. PLoS One. 11(3):e0149159. PMID: 26933885.

Zeng et al. 2015. Int J Pharm. 495(2):1028-37. PMID: 26403384.

De Ryck et al. 2015. AMB Express. 5:27. PMID: 25995981.

O'Callaghan et al. 2015. Mol Med Rep. :. PMID: 26005189.

Chai et al. 2012. J R Soc Interface. 9(77):3528-38. PMID: 22915635.

Mørck Nielsen et al. 2000. Int J Pharm. 200(2):261-70. PMID: 10867256.

Nielsen et al. 2000. Int J Pharm. 194(2):155-67. PMID: 10692640.

Jacobsen et al. 1999. Eur J Pharm Biopharm. 48(3):217-24. PMID: 10612032.

Nielsen et al. 1999. Int J Pharm. 185(2):215-25. PMID: 10460917.

Nielsen et al. 1999. J Control Release. 60(2-3):223-33. PMID: 10425328.

Pedersen et al. 1999. Drug Dev Ind Pharm. 25(4):463-70. PMID: 10194601.

Jacobsen et al. 1999. Eur J Oral Sci. 107(2):138-46. PMID: 10232463.

Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234.


Add a reference


This reagent does not have any reviews at the moment.